This article talks about the combination of Onc-201 and paxalisib for DIPG. It says that Onc-201 works by itself for DIPG but usually the tumor develops resistance to it through the P13K pathway. Paxalisib targets this P13K pathway so it makes sense to try the combination. They treated 2 patients under compassionate use and both had dramatic reductions in tumor volume, complete resolution of symptoms and extended survival. So they started a trial https://clinicaltrials.gov/ct2/show/NCT05009992 for the combination to use in DIPG and DMG. I will be watching this trial closely.